Loading news...
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Straumann Holding AG (SAUHY). But which of these two companies is the best option for those looking for undervalued stocks?
Henry Schein (NASDAQ: HSIC - Get Free Report) and McKesson (NYSE: MCK - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Risk and Volatility Henry Schein has a beta of
Chicago-based Zuckerman Investment Group increased its Henry Schein position by 72,040 shares in the third quarter. The overall position value went up by about $3.38 million from the previous period.
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in January: J.P. Morgan's Healthcare Investor Conference on Tuesday, January 13, 2026, at 3:00 p.m. PST / 6:00 p.m. EST, at The Westin St. Francis hotel in San Francisco. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.c.
Assenagon Asset Management S.A. decreased its holdings in Henry Schein, Inc. (NASDAQ: HSIC) by 52.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,480 shares of the company's stock after selling 23,586 shares during the period. Assenagon Asset Management
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) (the “Company”), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that it expects to appoint the Company's next CEO by mid-January 2026. Philip A. Laskawy, Lead Director for Henry Schein said, “We are pleased with the progress we have made in our search for Henry Schein's next CEO. The search process is nearing completion but will not be finalized before year.
Stock futures are quietly lower as investors unpack previously delayed GDP data for the third quarter
Henry Schein (NASDAQ: HSIC - Get Free Report) and McKesson (NYSE: MCK - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Valuation and Earnings This table compares Henry Schein and
Arrowstreet Capital Limited Partnership grew its stake in Henry Schein, Inc. (NASDAQ: HSIC) by 80.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 289,051 shares of the company's stock after purchasing an additional 129,077 shares during the period. Arrowstreet Capital
Henry Schein stands out as the largest global provider of healthcare products and services for office-based dental and medical practitioners, with a strong market share. HSIC continues to deliver solid growth, reporting Q3 revenue up 5.2% year-over-year and improved profitability across all segments, driven by internal growth and targeted programs. Management anticipates ongoing revenue and EBITDA growth, supported by demographic trends, increased healthcare access, and technological advancements like AI in dental care.
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
Henry Schein, Inc. (HSIC) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Henry Schein gains exclusive U.S. rights to Curodont, expanding its vVARDIS partnership and boosting expectations for a Dental business rebound.
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) today announced the expansion of its agreement with vVARDIS, which grants the Company exclusive U.S. distribution rights for the drill-free Curodont™ Repair Fluoride Plus (“Curodont”) product across all dental market segments, effective January 1, 2026. The strategic expansion broadens Henry Schein's previous exclusivity with the Swiss company, which was announced in 2024 for Dental Service Organizations (DSOs). Starting next ye.
HSIC gains momentum as Henry Schein One rolls out AI-powered dental workflows unveiled at the Greater New York Dental Meeting.
Alphabet shares rose 38% during the quarter. This represents a striking $810 billion increase in market value. Samsung shares rose 36% in the quarter, adding over $100 billion of market value. Samsung shares are finally starting to benefit from AI enthusiasm. Elevance's share price declined by 16%, making it our largest negative contributor.
AMERICAN FORK, Utah--(BUSINESS WIRE)--Coming off the heels of its announcement with Amazon Web Services, Henry Schein One, the leading provider of global dental technology, today unveils natively embedded AI and automation workflows. This includes Voice Notes, which helps practices close revenue gaps through clean claims, and modernize more effectively. “Our goal isn't piecemeal AI and automation — it's natively embedded AI with a purpose,” said Dr. Ryan Hungate, Chief Clinical and Strategy Off.
Shares of Teradyne advanced sharply as investors cheered the company's robust earnings and outlook for Teradyne's artificial intelligence compute testing business. Shares of Henry Schein declined as promotional activity to attract new customers in its online channel pressured margins. We exited our position in Centene and reallocated proceeds to other positions that we believed offered more attractive risk/reward opportunities.
Henry Schein, Inc. ( HSIC ) Jefferies London Healthcare Conference 2025 November 18, 2025 9:30 AM EST Company Participants Stanley Bergman - Executive Chairman & CEO Andrea Albertini - Chief Executive Officer of Global Distribution & Technology Graham Stanley - VP of Investor Relations & Strategic Finance Project Officer Conference Call Participants Michael Sarcone - Jefferies LLC, Research Division Presentation Michael Sarcone Jefferies LLC, Research Division Hi, everyone. My name is Mike Sarcone.
Insights from the Third Quarter 2025 13F Filing Mario Cibelli (Trades, Portfolio), a seasoned investor and founder of Marathon Partners Equity Management, rece